STOCK TITAN

[Form 4] Cardlytics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Cardlytics, Inc. (CDLX) – Form 4 insider transaction: Chief Legal & Privacy Officer Nicholas Hollmeyer reported the vesting of three restricted-stock-unit (RSU) tranches on 01-Jul-2025, converting a total of 12,788 shares of CDLX common stock. On 02-Jul-2025 he sold 5,271 shares at a weighted-average price of $1.7826 per share. According to the filing, the sale was executed solely to satisfy tax-withholding obligations generated by the RSU delivery.

Following the transactions, Hollmeyer’s direct ownership stands at 109,636 common shares. He also retains 39,945 unvested RSUs across three awards that continue to vest quarterly through 01-Apr-2026. No other insider relationships or indirect holdings were disclosed.

The activity represents a routine equity compensation event rather than a discretionary sale. The net effect is a modest increase in the executive’s equity exposure (shares acquired minus shares sold equals +7,517). Given CDLX’s low absolute share price, the dollar value of the tax-sale (~$9.4 k) is immaterial to the company and is unlikely to influence the investment thesis.

Cardlytics, Inc. (CDLX) – Transazione interna Form 4: Il Chief Legal & Privacy Officer Nicholas Hollmeyer ha dichiarato la maturazione di tre tranche di unità azionarie vincolate (RSU) il 01-lug-2025, convertendo un totale di 12.788 azioni ordinarie CDLX. Il 02-lug-2025 ha venduto 5.271 azioni a un prezzo medio ponderato di $1,7826 per azione. Secondo la documentazione, la vendita è stata effettuata esclusivamente per soddisfare gli obblighi fiscali derivanti dalla consegna delle RSU.

Dopo le transazioni, la proprietà diretta di Hollmeyer ammonta a 109.636 azioni ordinarie. Mantiene inoltre 39.945 RSU non maturate relative a tre premi che continueranno a maturare trimestralmente fino al 01-apr-2026. Non sono stati segnalati altri rapporti interni o partecipazioni indirette.

L’attività rappresenta un evento di compensazione azionaria ordinario piuttosto che una vendita discrezionale. L’effetto netto è un modesto incremento nell’esposizione azionaria dell’esecutivo (azioni acquisite meno azioni vendute pari a +7.517). Considerando il prezzo assoluto basso delle azioni CDLX, il valore in dollari della vendita per tasse (~9,4 mila $) è irrilevante per la società e difficilmente influenzerà la tesi d’investimento.

Cardlytics, Inc. (CDLX) – Transacción interna Formulario 4: El Chief Legal & Privacy Officer Nicholas Hollmeyer reportó la consolidación de tres tramos de unidades restringidas de acciones (RSU) el 01-jul-2025, convirtiendo un total de 12,788 acciones ordinarias de CDLX. El 02-jul-2025 vendió 5,271 acciones a un precio promedio ponderado de $1.7826 por acción. Según el informe, la venta se realizó únicamente para cubrir las obligaciones fiscales generadas por la entrega de las RSU.

Tras las transacciones, la propiedad directa de Hollmeyer es de 109,636 acciones ordinarias. También conserva 39,945 RSU no consolidadas correspondientes a tres premios que continúan consolidándose trimestralmente hasta el 01-abr-2026. No se revelaron otras relaciones internas ni participaciones indirectas.

La actividad representa un evento rutinario de compensación en acciones, no una venta discrecional. El efecto neto es un ligero aumento en la exposición accionaria del ejecutivo (acciones adquiridas menos acciones vendidas igual a +7,517). Dado el bajo precio absoluto de las acciones CDLX, el valor en dólares de la venta para impuestos (~$9.4 mil) es insignificante para la empresa y probablemente no influirá en la tesis de inversión.

Cardlytics, Inc. (CDLX) – Form 4 내부자 거래: 최고 법률 및 개인정보 책임자 Nicholas Hollmeyer는 2025년 7월 1일에 세 개의 제한 주식 단위(RSU) 트랜치가 확정되어 총 12,788주의 CDLX 보통주로 전환되었다고 보고했습니다. 2025년 7월 2일에는 5,271주를 주당 평균 가격 $1.7826에 매도했습니다. 제출 서류에 따르면, 이 매도는 RSU 지급으로 발생한 세금 원천징수 의무를 충족하기 위해서만 실행되었습니다.

거래 후 Hollmeyer의 직접 보유 주식은 109,636주입니다. 또한 2026년 4월 1일까지 분기별로 계속 확정되는 세 개의 상금에 걸쳐 39,945개의 미확정 RSU를 보유하고 있습니다. 다른 내부자 관계나 간접 보유는 공개되지 않았습니다.

이 활동은 임의 매도가 아닌 일상적인 주식 보상 이벤트를 나타냅니다. 순효과는 경영진의 주식 노출이 약간 증가한 것으로 (취득 주식 수에서 매도 주식 수를 뺀 값은 +7,517) 나타납니다. CDLX의 낮은 절대 주가를 고려할 때, 세금 매도 금액(~9,400달러)은 회사에 미미하며 투자 논리에 영향을 미치지 않을 가능성이 큽니다.

Cardlytics, Inc. (CDLX) – Transaction d’initié Formulaire 4 : Le Chief Legal & Privacy Officer Nicholas Hollmeyer a déclaré la levée de trois tranches d’unités d’actions restreintes (RSU) le 01-juil-2025, convertissant un total de 12 788 actions ordinaires CDLX. Le 02-juil-2025, il a vendu 5 271 actions à un prix moyen pondéré de 1,7826 $ par action. Selon le dépôt, la vente a été réalisée uniquement pour satisfaire aux obligations fiscales liées à la livraison des RSU.

Suite à ces transactions, la détention directe de Hollmeyer s’élève à 109 636 actions ordinaires. Il conserve également 39 945 RSU non acquises réparties sur trois attributions qui continuent de s’acquérir trimestriellement jusqu’au 01-avr-2026. Aucune autre relation d’initié ou détention indirecte n’a été divulguée.

Cette opération représente un événement de compensation en actions de routine plutôt qu’une vente discrétionnaire. L’effet net est une légère augmentation de l’exposition en actions de l’exécutif (actions acquises moins actions vendues = +7 517). Étant donné le faible cours absolu de l’action CDLX, la valeur en dollars de la vente pour impôts (~9,4 k$) est négligeable pour la société et est peu susceptible d’influencer la thèse d’investissement.

Cardlytics, Inc. (CDLX) – Form 4 Insider-Transaktion: Chief Legal & Privacy Officer Nicholas Hollmeyer meldete die Freigabe von drei Tranchen von Restricted-Stock-Units (RSUs) am 01. Juli 2025, wodurch insgesamt 12.788 Aktien von CDLX-Stammaktien umgewandelt wurden. Am 02. Juli 2025 verkaufte er 5.271 Aktien zu einem gewichteten Durchschnittspreis von $1,7826 pro Aktie. Laut der Meldung erfolgte der Verkauf ausschließlich zur Erfüllung der steuerlichen Abzugspflichten, die durch die RSU-Zuteilung entstanden sind.

Nach den Transaktionen hält Hollmeyer direkt 109.636 Stammaktien. Zudem besitzt er 39.945 nicht freigegebene RSUs aus drei Auszeichnungen, die weiterhin vierteljährlich bis zum 01. April 2026 freigegeben werden. Weitere Insider-Beziehungen oder indirekte Beteiligungen wurden nicht offengelegt.

Die Aktivität stellt ein routinemäßiges Aktienvergütungsereignis dar und keine diskretionäre Veräußerung. Der Nettoeffekt ist ein moderater Anstieg der Aktienexponierung des Geschäftsführers (erworbene Aktien minus verkaufte Aktien = +7.517). Angesichts des niedrigen absoluten Aktienkurses von CDLX ist der Dollarwert des Steuerverkaufs (~9,4 Tsd. $) für das Unternehmen unerheblich und wird die Investmentthese wahrscheinlich nicht beeinflussen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting; small tax-related sale, immaterial to valuation.

The filing documents standard quarterly RSU vesting for a senior officer. Although 5,271 shares were sold, the purpose was tax withholding, not discretionary profit-taking, limiting any negative signal. Net share ownership increased, and the remaining 39.9 k RSUs sustain management’s long-term incentive alignment. With an estimated sale value below $10 k and no change to executive roles or corporate strategy, I view the disclosure as neutral from a market-impact perspective.

Cardlytics, Inc. (CDLX) – Transazione interna Form 4: Il Chief Legal & Privacy Officer Nicholas Hollmeyer ha dichiarato la maturazione di tre tranche di unità azionarie vincolate (RSU) il 01-lug-2025, convertendo un totale di 12.788 azioni ordinarie CDLX. Il 02-lug-2025 ha venduto 5.271 azioni a un prezzo medio ponderato di $1,7826 per azione. Secondo la documentazione, la vendita è stata effettuata esclusivamente per soddisfare gli obblighi fiscali derivanti dalla consegna delle RSU.

Dopo le transazioni, la proprietà diretta di Hollmeyer ammonta a 109.636 azioni ordinarie. Mantiene inoltre 39.945 RSU non maturate relative a tre premi che continueranno a maturare trimestralmente fino al 01-apr-2026. Non sono stati segnalati altri rapporti interni o partecipazioni indirette.

L’attività rappresenta un evento di compensazione azionaria ordinario piuttosto che una vendita discrezionale. L’effetto netto è un modesto incremento nell’esposizione azionaria dell’esecutivo (azioni acquisite meno azioni vendute pari a +7.517). Considerando il prezzo assoluto basso delle azioni CDLX, il valore in dollari della vendita per tasse (~9,4 mila $) è irrilevante per la società e difficilmente influenzerà la tesi d’investimento.

Cardlytics, Inc. (CDLX) – Transacción interna Formulario 4: El Chief Legal & Privacy Officer Nicholas Hollmeyer reportó la consolidación de tres tramos de unidades restringidas de acciones (RSU) el 01-jul-2025, convirtiendo un total de 12,788 acciones ordinarias de CDLX. El 02-jul-2025 vendió 5,271 acciones a un precio promedio ponderado de $1.7826 por acción. Según el informe, la venta se realizó únicamente para cubrir las obligaciones fiscales generadas por la entrega de las RSU.

Tras las transacciones, la propiedad directa de Hollmeyer es de 109,636 acciones ordinarias. También conserva 39,945 RSU no consolidadas correspondientes a tres premios que continúan consolidándose trimestralmente hasta el 01-abr-2026. No se revelaron otras relaciones internas ni participaciones indirectas.

La actividad representa un evento rutinario de compensación en acciones, no una venta discrecional. El efecto neto es un ligero aumento en la exposición accionaria del ejecutivo (acciones adquiridas menos acciones vendidas igual a +7,517). Dado el bajo precio absoluto de las acciones CDLX, el valor en dólares de la venta para impuestos (~$9.4 mil) es insignificante para la empresa y probablemente no influirá en la tesis de inversión.

Cardlytics, Inc. (CDLX) – Form 4 내부자 거래: 최고 법률 및 개인정보 책임자 Nicholas Hollmeyer는 2025년 7월 1일에 세 개의 제한 주식 단위(RSU) 트랜치가 확정되어 총 12,788주의 CDLX 보통주로 전환되었다고 보고했습니다. 2025년 7월 2일에는 5,271주를 주당 평균 가격 $1.7826에 매도했습니다. 제출 서류에 따르면, 이 매도는 RSU 지급으로 발생한 세금 원천징수 의무를 충족하기 위해서만 실행되었습니다.

거래 후 Hollmeyer의 직접 보유 주식은 109,636주입니다. 또한 2026년 4월 1일까지 분기별로 계속 확정되는 세 개의 상금에 걸쳐 39,945개의 미확정 RSU를 보유하고 있습니다. 다른 내부자 관계나 간접 보유는 공개되지 않았습니다.

이 활동은 임의 매도가 아닌 일상적인 주식 보상 이벤트를 나타냅니다. 순효과는 경영진의 주식 노출이 약간 증가한 것으로 (취득 주식 수에서 매도 주식 수를 뺀 값은 +7,517) 나타납니다. CDLX의 낮은 절대 주가를 고려할 때, 세금 매도 금액(~9,400달러)은 회사에 미미하며 투자 논리에 영향을 미치지 않을 가능성이 큽니다.

Cardlytics, Inc. (CDLX) – Transaction d’initié Formulaire 4 : Le Chief Legal & Privacy Officer Nicholas Hollmeyer a déclaré la levée de trois tranches d’unités d’actions restreintes (RSU) le 01-juil-2025, convertissant un total de 12 788 actions ordinaires CDLX. Le 02-juil-2025, il a vendu 5 271 actions à un prix moyen pondéré de 1,7826 $ par action. Selon le dépôt, la vente a été réalisée uniquement pour satisfaire aux obligations fiscales liées à la livraison des RSU.

Suite à ces transactions, la détention directe de Hollmeyer s’élève à 109 636 actions ordinaires. Il conserve également 39 945 RSU non acquises réparties sur trois attributions qui continuent de s’acquérir trimestriellement jusqu’au 01-avr-2026. Aucune autre relation d’initié ou détention indirecte n’a été divulguée.

Cette opération représente un événement de compensation en actions de routine plutôt qu’une vente discrétionnaire. L’effet net est une légère augmentation de l’exposition en actions de l’exécutif (actions acquises moins actions vendues = +7 517). Étant donné le faible cours absolu de l’action CDLX, la valeur en dollars de la vente pour impôts (~9,4 k$) est négligeable pour la société et est peu susceptible d’influencer la thèse d’investissement.

Cardlytics, Inc. (CDLX) – Form 4 Insider-Transaktion: Chief Legal & Privacy Officer Nicholas Hollmeyer meldete die Freigabe von drei Tranchen von Restricted-Stock-Units (RSUs) am 01. Juli 2025, wodurch insgesamt 12.788 Aktien von CDLX-Stammaktien umgewandelt wurden. Am 02. Juli 2025 verkaufte er 5.271 Aktien zu einem gewichteten Durchschnittspreis von $1,7826 pro Aktie. Laut der Meldung erfolgte der Verkauf ausschließlich zur Erfüllung der steuerlichen Abzugspflichten, die durch die RSU-Zuteilung entstanden sind.

Nach den Transaktionen hält Hollmeyer direkt 109.636 Stammaktien. Zudem besitzt er 39.945 nicht freigegebene RSUs aus drei Auszeichnungen, die weiterhin vierteljährlich bis zum 01. April 2026 freigegeben werden. Weitere Insider-Beziehungen oder indirekte Beteiligungen wurden nicht offengelegt.

Die Aktivität stellt ein routinemäßiges Aktienvergütungsereignis dar und keine diskretionäre Veräußerung. Der Nettoeffekt ist ein moderater Anstieg der Aktienexponierung des Geschäftsführers (erworbene Aktien minus verkaufte Aktien = +7.517). Angesichts des niedrigen absoluten Aktienkurses von CDLX ist der Dollarwert des Steuerverkaufs (~9,4 Tsd. $) für das Unternehmen unerheblich und wird die Investmentthese wahrscheinlich nicht beeinflussen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lynton Nicholas Hollmeyer

(Last) (First) (Middle)
675 PONCE DE LEON AVENUE NE
SUITE 4100

(Street)
ATLANTA GA 30308

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cardlytics, Inc. [ CDLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal & Privacy Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 M 10,629 A (1) 112,748 D
Common Stock 07/01/2025 M 581 A (1) 113,329 D
Common Stock 07/01/2025 M 1,578 A (1) 114,907 D
Common Stock 07/02/2025 S 5,271(2) D $1.7826(3) 109,636 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 07/01/2025 M 10,629 (4) (4) Common Stock 10,629 $0 31,889 D
Restricted Stock Unit (1) 07/01/2025 M 581 (5) (5) Common Stock 581 $0 1,744 D
Restricted Stock Units (1) 07/01/2025 M 1,578 (6) (6) Common Stock 1,578 $0 6,312 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer.
2. Shares were sold solely to satisfy tax withholding obligations that resulted from the delivery of shares of common stock for RSUs that vested on July 1, 2025. The Reporting Person did not sell shares for any other purpose.
3. The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.8451, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3).
4. The RSU award was originally for 85,035 shares. The RSU award vested or will vest in eight equal installments on July 1, 2024, October 1, 2024, January 1, 2025, April 1, 2025, July 1, 2025, October 1, 2025, January 1, 2026 and April 1, 2026, provided that the Reporting Person remains employed by the Issuer on such vesting date.
5. The RSU award was originally for 9,299 shares. Twenty-five percent (25%) of the shares under this award vested on April 1, 2023, with the remaining 75% vesting quarterly over the subsequent three years in equal amounts thereafter provided the Reporting Person continuously provides service to the Issuer through the vesting date.
6. This RSU award was originally for 25,247 shares. Twenty-five percent (25%) of the shares under this award vested on July 1, 2023, with the remaining 75% vesting quarterly over the subsequent three years in equal amounts thereafter provided the Reporting Person continuously provides service to the Issuer through the vesting date.
Remarks:
/s/ Nick Lynton 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CDLX shares did Nicholas Hollmeyer acquire through RSU vesting?

12,788 shares vested and converted to common stock on 01-Jul-2025.

What was the sale price for the CDLX shares sold on 02-Jul-2025?

The weighted-average sale price was $1.7826 per share, within a $1.66–$1.8451 range.

How many CDLX shares does the insider own after the transactions?

Direct ownership is 109,636 common shares plus 39,945 unvested RSUs.

Why were shares sold by the insider?

All shares sold were solely to cover tax-withholding obligations arising from RSU vesting.

Do the transactions indicate a change in insider sentiment toward Cardlytics (CDLX)?

The filing appears routine; net ownership increased, so it does not signal a bearish outlook.
Cardlytics

NASDAQ:CDLX

CDLX Rankings

CDLX Latest News

CDLX Latest SEC Filings

CDLX Stock Data

97.65M
51.06M
5.12%
57.68%
17.68%
Advertising Agencies
Services-computer Programming, Data Processing, Etc.
Link
United States
ATLANTA